Kiora Pharmaceuticals
Most recent annual filing: 2026-01-15
- KIO-104 toplinelate 2026KIO-104 topline, late 2026, material
- Tranche A-1 warrants corporate updateJan 2027Tranche A-1 warrants corporate update, Jan 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Technology platforms
Ion Channel Modulator
Novel ion channel modulator platform with membrane-calming effects; primary focus on retinal disease (reducing pathological retinal hyperactivity); exploratory expansion into neurological disorders including epilepsy where neuronal hyperexcitability is implicated
Biotech Distilled coverage (5)
- 2026-08-19 UPDATE: Kiora Pharmaceuticals (KPRX) - The Last Map Pin Gets Filled 🔒 Paid
- 2026-08-08 UPDATE: Kiora Pharmaceuticals (KPRX) - The Runway Stretches, and a Catalyst Quietly Moves Up 🔒 Paid
- 2026-04-27 UPDATE: KIORA PHARMACEUTICALS INC (KPRX) - Perceptive Shows Up, Nature Medicine Prints, and the Warrant Structure Tells You the Plan 🔒 Paid
- 2026-03-28 UPDATE: Kiora Pharmaceuticals (KPRX) - A 12-Month Delay, a $4.6M Impairment, and the Value of Deep-Pocketed Partners 🔒 Paid
- 2026-03-09 Kiora Pharmaceuticals (KPRX): Scientific Deep Dive for KIO-301 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.